NCT02944435View on ClinicalTrials.gov

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

CB-839 Capsules

3 x 200 mg CB-839 Capsules (Reference Formulation)

DRUG

CB-839 Tablets

3 x 200 mg CB-839 Tablets (Test Formulation)

Trial Locations (1)

58104

Algorithme Pharma USA, LLC, Fargo

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY